Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Biomedica Regulatory News (OXB)

Share Price Information for Oxford Biomedica (OXB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 306.50
Bid: 309.00
Ask: 310.50
Change: -8.50 (-2.70%)
Spread: 1.50 (0.485%)
Open: 311.50
High: 312.50
Low: 302.00
Prev. Close: 315.00
OXB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

2 Sep 2015 15:12

RNS Number : 8961X
Oxford Biomedica PLC
02 September 2015
 

 

For filings with the FSA include the annex

For filings with issuer exclude the annex

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: ii

Oxford Biomedica PLC

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

X

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify):

3. Full name of person(s) subject to thenotification obligation: iii

Third National Swedish Pension Fund

4. Full name of shareholder(s)  (if different from 3.):iv

5. Date of the transaction and date onwhich the threshold is crossed orreached: v

2015-09-01

6. Date on which issuer notified:

2015-09-02

7. Threshold(s) that is/are crossed orreached: vi, vii

3%

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

GB0006648157

78,317,715

78,317,715

77,176,027

77,176,027

2.99%

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Expirationdate xiii

Exercise/Conversion Period xiv

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

% of votingrights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financialinstrument

Exercise price

Expiration date xvii

Exercise/Conversion period xviii

Number of voting rights instrument refers to

 

% of voting rights xix, xx

 

 

 

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

77,176,027

2.99%

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi

 

 

Proxy Voting:

10. Name of the proxy holder:

11. Number of voting rights proxy holder will ceaseto hold:

12. Date on which proxy holder will cease to holdvoting rights:

13. Additional information:

14. Contact name:

15. Contact telephone number:

 

Note: Annex should only be submitted to the FSA not the issuer

Annex: Notification of major interests in share

A: Identity of the persons or legal entity subject to the notification obligation

Full name

(including legal form of legal entities)

 

Third National Swedish Pension Fund

Contact address

(registered office for legal entities)

 

Vasagatan 7, 111 91 Stockholm, Sweden

Phone number & email

 

+468-555 17 100

Other useful information

(at least legal representative for legal persons)

 

Mikael Sedolin

B: Identity of the notifier, if applicable

Full name

 

Sebastian Mossfeldt

Contact address

 

Vasagatan 7, 111 91 Stockholm, Sweden

Phone number & email

 

+468-555 17 162, Sebastian.mossfeldt@ap3.se

Other useful information

(e.g. functional relationship with the person or legal entity subject to the notification obligation)

C: Additional information

For notes on how to complete form TR-1 please see the FSA website.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLUUASRVRAKRAR
Date   Source Headline
18th Jun 20197:15 amEQSHardman & Co Research: Oxford BioMedica (OXB): De-leveraging the balance sheet
10th Jun 20192:34 pmRNSDirector/PDMR Shareholding
6th Jun 20191:08 pmRNSAxovant update on 1st cohort of Sunrise-PD trial
6th Jun 201911:39 amRNSHolding(s) in Company
5th Jun 201912:06 pmRNSHoldings in Company
4th Jun 20195:38 pmRNSHoldings in Company
4th Jun 20199:59 amRNSTotal Voting Rights
3rd Jun 20196:06 pmRNSHolding(s) in Company
3rd Jun 201910:31 amRNSTotal Voting Rights
29th May 20196:19 pmRNSExercise of Subscription Option by Novo Holdings
29th May 20191:06 pmRNSResult of AGM
28th May 20197:00 amRNSStrategic Investment by Novo Holdings A/S
23rd May 20196:04 pmRNSDirector Dealings / Market Share Purchase
2nd May 20192:53 pmRNSLong Term Incentive Plan Option Grant
1st May 201912:52 pmRNSREPLACEMENT: Total Voting Rights
1st May 201911:33 amRNSTotal Voting Rights
30th Apr 20195:38 pmRNSHoldings in Company
30th Apr 20191:35 pmRNSOxford Biomedica to present at the ASGCT
30th Apr 20191:15 pmRNSAxovant doses second cohort of AXO-Lenti-PD
25th Apr 20193:38 pmRNSDirector Dealings / Market Share Purchase
23rd Apr 20191:47 pmRNSDeferred Bonus Plan and LTIP Option Grants
23rd Apr 201911:38 amRNSDirector Dealings / Market Share Transactions
18th Apr 20195:33 pmRNSExercise of warrants
18th Apr 20197:00 amRNSAnnual Report and Accounts & AGM Notification
1st Apr 201911:40 amRNSTotal Voting Rights
26th Mar 201912:57 pmRNSDirector Dealings / Market Share Purchase
26th Mar 20198:25 amRNSJapanese approval of Kymriah® (tisagenlecleucel)
14th Mar 20197:00 amRNSPreliminary Results
12th Mar 20197:00 amRNSOXB announces R&D collaboration with Microsoft
11th Mar 201910:38 amRNSAxovant's update on Phase 2 trial of AXO-Lenti-PD
1st Mar 20199:30 amRNSTotal Voting Rights
25th Feb 201912:23 pmRNSDirector Dealings / Market Share Purchase
8th Feb 20197:00 amRNSNotice of Results
7th Feb 201911:49 amRNSDirector/PDMR Shareholding
7th Feb 20199:22 amRNSUpdate on programmes outlicensed to Sanofi
6th Feb 201911:00 amRNSDirector Dealings / Market Share Transactions
5th Feb 201910:22 amRNSDirector Dealings / Market Share Purchase
1st Feb 201910:00 amRNSTotal Voting Rights
24th Jan 201911:20 amRNSDirector Dealings / Market Share Purchase
3rd Jan 201912:20 pmRNSBlock listing Interim Review
2nd Jan 201910:17 amRNSTotal Voting Rights
21st Dec 20181:16 pmRNSDirector Dealings / Market Share Purchase
6th Dec 20184:11 pmRNSAxovant FDA meeting feedback
3rd Dec 20189:53 amRNSTotal Voting Rights
3rd Dec 20187:00 amRNSLonger term Kymriah efficacy and safety data
23rd Nov 201810:41 amRNSDirector Dealings
23rd Nov 20187:00 amRNSOxford Biomedica form digital framework initiative
9th Nov 20187:00 amRNSBlock listing application
1st Nov 20182:41 pmRNSTotal Voting Rights
25th Oct 20187:00 amRNSAxovant Doses First Patient with AXO-Lenti-PD

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.